Cytokinetics, Inc. (CYTK) Posts Q2 EPS Loss of $0.23, Well Below Expectations
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $78.94 +0.20%
Revenue Growth %: -75.4%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -75.4%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $6.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital on Cytokinetics (CYTK): 'The stock is significantly undervalued despite today's move'
- PowerFleet, Inc. (AIOT) Misses Q1 EPS by 2c ; Offers Guidance
- Safe Bulkers (SB) Tops Q1 EPS by 7c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
